hotspot -WSS

hotspot

author：comprehensive 2025-09-30 14:34:08 - browse：67455

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Solving academic medical centers' existential crisis

WSS

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

In venture capital firm's success, lessons for turning crisis into profit

Arc Institute generative AI designs new CRISPR systems

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Germany receives 178 compensation applications from gay servicepeople over discrimination

Sage's campaign to raise awareness of postpartum depression hits a nerve

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

United colonoscopy coverage change 'may cost lives,' doctors say

‘The Bear’ and hospitality in hospitals

Guidelines to prevent youth baseball injuries need more muscle

Case highlights the risks of experimental stem cell therapy

Novavax promises a turnaround & Lilly roils the obesity market

HIV vaccine remains elusive. Immunologists keep trying new ideas

Supreme Court strikes down use of affirmative action

Case highlights the risks of experimental stem cell therapy

entertainment

FTX founder Sam Bankman

Germany receives 178 compensation applications from gay servicepeople over discrimination

Military medical care influenced by rank and race, new study finds

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Astronauts get first look at the spacecraft that will fly them around the moon

CDC launches VaccineFinder tool to locate Covid

focus

entertainment

entertainment

entertainment